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Abstract
Background: Advances in gene transfer techniques have provided long-term, safe and stable transduction of retinal cells
following subretinal injection with adeno-associated viral (AAV) vectors. In this study we investigated whether subretinal
injection of AAV2-murine IL-27p28 vector was effective in inhibiting experimental autoimmune uveoretinitis (EAU) induced
in B10RIII mice.
Methodology/Principal Findings: An AAV2 vector encoding the murine IL-27p28 gene (rAAV2-CMV-mIL-27p28) was
prepared and subretinally injected into B10RIII mice (4.35610
8 vector genome (v.g.)). AAV2 vector mediating green
fluorescent protein (rAAV2-CMV-GFP) served as a control (5610
8 v.g.). The concentration of mIL-27p28 in homogenized
eyes and serum was assayed by enzyme linked immunosorbent assay (ELISA) after subretinal injection. Human IRBP161–180
peptide and Complete Freund’s Adjuvant were injected into mice receiving either the rAAV2-CMV-mIL-27p28 or rAAV2-
CMV-GFP vector. EAU was evaluated clinically and pathologically. The level of IL-17 and IL-10 in homogenized eyes was
measured on day 12 and day 21 following immunization. Delayed type hypersensitivity (DTH) and IRBP161–180–specific
proliferation of lymphocytes from the spleen and lymph nodes were assayed to examine the influence of the subretinal
delivery of rAAV2-CMV-mIL-27p28 on the systemic immune response. IL-27p28 was detectable by ELISA within the eyes
from two weeks following subretinal injection of the rAAV2-CMV-mIL-27p28 vector and showed a sustained high expression
from day 14 to 9 months with a highest expression at 5 months. Subretinal injection of the vector significantly attenuated
the severity of EAU disease clinically and pathologically in association with a significantly decreased IL-17 expression and an
increased IL-10 expression. The IL-27p28 vector did not affect the systemic immune response, as determined by DTH and
IRBP161–180–specific lymphocyte proliferation.
Conclusions/Significance: A high and stable expression of IL-27p28 was observed for at least 9 months following subretinal
delivery of rAAV2-CMV-mIL-27p28. The amelioration of EAU disease severity was associated with a decreased IL-17
expression and an increased IL-10 expression.
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Introduction
Uveitis is a sight-threatening inflammatory disease that mostly
affects young adults and remains one of the important causes of
visual impairment [1–3]. Corticosteroids and other immunosup-
pressive drugs have been widely used for its treatment [4–5].
However, these drugs may cause a number of side effects that can
potentially be life-threatening.
Interleukin (IL)-27 is a recently identified member of the IL-6/
IL-12 family. It is a heterodimeric cytokine consisting of 2
subunits, Epstein-Barr-induced gene 3 (EBI3) and IL-27p28 [6]. It
has been shown to play an important role as an inhibitor of both
Th1 and Th17 responses and may thus control autoimmune
mediated inflammation [7–11]. Recent studies have shown that
systemic administration of exogenous IL-27 significantly inhibits
the activity of experimental autoimmune encephalomyelitis (EAE),
EAU and collagen-induced arthritis (CIA) in animal models [12–
14]. In addition, endogenous production of IL-27 by retinal cells
has been shown to inhibit the intraocular inflammation in EAU
[15]. IL-27p28 and EBI3 are secreted independently, and both
subunits are not expressed by the same cells [16–17]. The finding
that the IL-27p28 can be secreted in the absence of EBI3 suggests
that this subunit may have an independent function. Purified IL-
27p28, like heterodimeric IL-27, was capable of suppressing IL-17
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+ T cells in vitro [18]. Expression of IL-27p28
has been shown to result in a modest delay in the onset and
severity of EAE [19].
Remarkable success of gene therapy has been achieved in
human and animal models for various retinal diseases [20–23].
The eye is an organ particularly suitable for gene therapy due to
the following reasons [24]. Various routes of delivery can be used
to target layers in the eye under direct vision and the application of
AAV vector leads to a long-term and stable gene transfer instead
of having to use repeated injections and high dose administration
of recombinant cytokines. In addition, single and low dose
administration of AAV vector and the ocular immune privilege
may reduce the immunogenicity. The elicited minimal host
immune response following intraocular injection does not create
retinal toxicity nor does it inhibit transgene expression [25–26].
Although AAV-mediated clinical gene therapy trials for diseases
involving different organs have been approved (http://www.wiley.
com/legacy/wileychi/genmed/clinical/), only few studies have
been performed in the EAU model [27–28]. In this study we
injected rAAV2-CMV-mIL-27p28 subretinally into the B10RIII
mice, and longitudinally evaluated the expression of IL-27p28
within the eye for a time period of 9 months. The results showed a
high and stable IL-27p28 expression within the eye and significant
inhibitory effects on EAU. Moreover, this inhibitory effect was
associated with a decreased IL-17 expression and an up-regulated
IL-10 expression within the eye.
Results
IL-27p28 Expression following Subretinal Injection of
rAAV2-CMV-mIL-27p28 Vector
A group of mice was injected subretinally with rAAV2-CMV-
mIL-27p28 (4.356108 v.g.). The IL-27p28 level in supernatants
from homogenized eyes obtained at different time points was
assayed by an IL-27p28 specific ELISA. The result showed that
IL-27p28 expression was detectable on day 14 (mean 7.916 ng/
ml) and increased on day 21 (mean 10.076 ng/ml). A high and
stable level of IL-27p28 expression was observed from day 42
(mean 9.011 ng/ml) up to day 150 (mean 13.472 ng/ml) and was
followed by a decreased expression nine months after injection (the
last detection point) (Figure 1). IL-27p28 could not be detected in
the contralateral uninjected eyes or in rAAV2-CMV-GFP injected
eyes at the various time points included in our study. It could also
not be detected in undiluted serum over time.
The Effect of rAAV2-CMV-mIL-27p28 on EAU
All B10RIII mice immunized with 50 mg human IRBP161–180
peptide emulsified in CFA showed a clinically visible EAU. The
inflammation appeared on day 8 or 9 after immunization, reached
its peak on day 12 and was followed by a gradual regression. No
inflammation was observed in mice receiving CFA alone.
To test the effect of rAAV2-CMV-mIL-27p28 on EAU, it was
subretinally injected into the right eyes of mice. rAAV2-CMV-
GFP (5610
8 v.g.) control vector was injected into the contralateral
eye of the same animal and served as an internal control [27].
Another group of mice only receiving a subretinal injection of PBS
served as a separate control. All mice were subsequently
immunized with IRBP161–180 peptide emulsified in CFA 3 weeks
after subretinal injection.
Obvious inflammatory reaction, as evidenced by conjunctival
hyperemia, ciliary injection, corneal edema, aqueous cells and
posterior synechiae, was observed in PBS or rAAV2-CMV-GFP
injected eyes (Figure 2A, B). However, in rAAV2-CMV-mIL-
27p28 treated eyes, a significantly decreased inflammatory
reaction (Figure 2C) was observed as compared to PBS or
rAAV2-CMV-GFP injected controls (p=0.024, p,0.001, respec-
tively) (Figure 2D). Histological examination on day 14 showed a
severe intraocular inflammation as evidenced by massive infiltra-
tion of inflammatory cells throughout all retinal layers and the
choroid, intensive retinal vasculitis and destruction of the retinal
architecture, as well as photoreceptor damage in the PBS injected
eyes and rAAV2-CMV-GFP injected control eyes (Figure 3A, B).
However, only scattered infiltration of inflammatory cells into the
retina and choroid was observed in rAAV2-CMV-mIL-27p28
treated eyes (Figure 3C). Histopathological grading showed that
PBS injected eyes (EAU grade, 3.0860.66) and rAAV2-CMV-
GFP injected eyes (EAU grade, 2.8961.05) had much more severe
inflammation as compared with the rAAV2-CMV-mIL-27p28
treated eyes (EAU grade, 160.61) (p=0.006, p=0.003, respec-
tively) (Figure 3D).
The Effect of rAAV2-CMV-mIL-27p28 on the Level of IL-17
and IL-10 within the Eyes
In order to evaluate whether the inhibitory effect of rAAV2-
CMV-mIL-27p28 on EAU activity was associated with modula-
tion of relevant cytokines, we measured the expression of IFN-c,
IL-17 and IL-10 within the eyes (figure 4A, B, C). The result
showed that there was no detectable expression of IFN-c and IL-
17 within the normal eyes. An increased expression of these two
cytokines was observed following immunization with IRBP161–180
peptide and CFA. A significantly higher expression for both IFN-c
and IL-17 was noted on day 12 as compared to day 21. However
there was no difference concerning IL-10 expression between day
12 and 21. Subretinal injection of rAAV2-CMV-mIL-27p28 was
associated with a significantly lower IL-17 expression on day 12 as
compared with rAAV2-CMV-GFP treated groups. On the other
hand we observed an increased IL-10 expression on both day 12
and 21 in rAAV2-CMV-mIL-27p28 injected eyes. No effect was
found on IFN-c expression between day 12 or day 21 when
comparing GFP with IL-27p28 vector injected eyes.
Effects of Subretinal Injection of rAAV2-CMV-mIL-27p28
on the Systemic Immune Response
To evaluate the impact of rAAV2-CMV-mIL-27p28 subretinal
injection on the immune system, we measured DTH in vivo,
Figure 1. The expression of transgene following subretinal
injection of rAAV2-CMV-mIL-27p28. The intraocular IL-27p28
levels at various time points show that IL-27p28 expression is stable
over 90 days, its expression reaches a peak on day 150 and remains
detectable until 9 months. Results are expressed as the mean 6
standard deviation. (n=3).
doi:10.1371/journal.pone.0037773.g001
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vitro. There was no difference concerning the DTH response
among mice receiving PBS subretinal injection, mice receiving
rAAV2-CMV-mIL-27p28 and mice receiving rAAV2-CMV-GFP
subretinal injection (Figure 5A).
A similar lymphocyte proliferation upon stimulation with
IRBP161–180 peptide was observed in both rAAV2-CMV-mIL-
27p28 treated mice and rAAV2-CMV-GFP treated mice as
compared with PBS treated controls. ConA could significantly
lead to a much stronger lymphocyte proliferation as compared
to IRBP161–180 peptide in these three groups. There was no
difference concerning lymphocyte proliferation among PBS
treated mice, rAAV2-CMV-mIL-27p28 treated mice and
rAAV2-CMV-GFP treated mice (Figure 5B). Similarly the
production of both IFN-c and IL-17 by the lymphocytes from
mice immunized with IRBP161–180 peptide and CFA was the
same with that from PBS treated controls upon stimulation
either with IRBP161–180 peptide or with ConA. ConA had a
much stronger stimulation on the production of both cytokines
as compared with IRBP161–180 peptide. There was no difference
concerning the production of both cytokines among PBS treated
mice, rAAV2-CMV-mIL-27p28 treated mice and rAAV2-CMV-
GFP treated mice (Figure 5C, D). Lymphocytes from the tested
three groups did not show a detectable proliferation, IL-17
Figure 2. Clinical evaluation of EAU activity. rAAV2-CMV-mIL-27p28 was subretinally injected into the eye, PBS and rAAV2-CMV-GFP were used
as controls. Three weeks after injection, mice were immunized to induce EAU with IRBP161–180 peptide and slit lamp microscopy was used to examine
ocular inflammation. Images show significantly more severe inflammation in the PBS (A) and rAAV2-CMV-GFP injected eyes (B) as compared with the
rAAV2-CMV-mIL-27p28 treated eye (C). Clinical scoring on day 12 after immunization (D) showed that the PBS injected eyes had a score of 1.86 (60.8)
and the rAAV2-CMV-GFP injected eyes reached a mean clinical score of 2.25 (60.59), whereas the score of rAAV2-CMV-mIL-27p28 treated eyes was 1
(60.24, p=0.024, p,0.001, respectively). The scores of three chosen eye pictures are 3, 3 and 0.5, respectively. Each point represents an individual
eye, the average scores of each group are denoted by the horizontal lines.
doi:10.1371/journal.pone.0037773.g002
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alone.
Discussion
In this study we showed that subretinal injection of rAAV2-
CMV-mIL-27p28 in the mouse resulted in a high and stable IL-
27p28 expression for at least 9 months. The amelioration of EAU
disease severity in B10RIII mice was found to be associated with a
decreased IL-17 expression and an increased IL-10 expression in
rAAV2-CMV-mIL-27p28 injected eyes.
As IL-27p28 may play an important role in the regulation of
autoimmune inflammation, we aimed to investigate its possible
therapeutical effects using EAU as a model and gene transfer as a
method of drug delivery. We successfully prepared the recombi-
nant viral vector encoding mIL-27p28, based on adeno-associated
virus, which provides a good vehicle for long-term safe and stable
gene transfer. The present result revealed a prolonged local
intraocular expression of mIL-27p28 following subretinal injection
of rAAV2-CMV-mIL-27p28. The expression of IL-27p28 was
10.076 ng/ml (mean) within the eye after 21 days injection with
0.5 ml rAAV2-CMV-IL-27p28 vector (8.7610
11 v.g./ml). Trans-
duction efficiency was also analyzed by histochemistry and showed
uniform low grade transfer throughout the retina with strongest
expression in the RPE, photoreceptor and outer plexiform layers
(data not shown). These findings confirmed earlier studies from
our group showing that the use of this vector system results in a
specific localization within the layers of RPE cells and photore-
Figure 3. Histological examination on day 14 of EAU. Images of histological analysis show severe retinal folding, destruction, damage of the
photoreceptor layer and massive inflammatory cell infiltration in the retina and the choroid, as well as intensive vasculitis in PBS injected eyes (A),
moderate infiltration, moderate photoreceptor cell damage and medium-sized granulomas in rAAV2-CMV-GFP injected eyes (B). However, a minor
infiltration of cells was observed in the choroid in rAAV2-CMV-mIL-27p28 treated eye (C). (hematoxylin eosin staining, magnification 6200)
Comparing PBS injected and rAAV2-CMV-GFP injected eyes with rAAV2-CMV-mIL-27p28 treated eyes showed a reduced EAU histological grade (D,
p=0.006, p=0.003, respectively). The scores of the three chosen eye section are 4, 3 and 0.5, respectively. Each point is the score of an individual eye,
the mean scores of each group are denoted by the horizontal lines.
doi:10.1371/journal.pone.0037773.g003
IL-27p28 Gene Therapy in EAU
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likely that subretinal injection of rAAV2-CMV-mIL-27p28, does
not interfere with systemic function, as partially demonstrated by
its ineffectiveness in the systemic immune response including
lymphocyte proliferation and production of relevant cytokines.
For the purpose of examining the effect of IL-27p28 on
EAU, we induced a clinically obvious intraocular inflammation
in B10RIII mice by immunization with IRBP161–180 peptide and
CFA. Subretinal injection of rAAV2-CMV-mIL-27p28 signifi-
cantly attenuated the EAU activity, both clinically and
pathologically. The fact that it not only blocked posterior
uveitis but also inhibited anterior segment inflammation can be
explained by the fact that the secreted IL-27p28 protein could
diffuse from the posterior segment towards the front of the eye
with the natural fluid flow [30]. As IFN-c and IL-17 play an
important role in the pathogenesis of EAU and IL-10 has a
negative regulatory effect [31–32], we further investigated
whether the inhibitory effect of subretinal injection of rAAV2-
CMV-mIL-27p28 on this model was mediated by these
cytokines. Induction of EAU was associated with a markedly
increased intraocular expression of IFN-c and IL-17 at the peak
of inflammation. Subretinal injection of rAAV2-CMV-mIL-
27p28 significantly inhibited the IL-17 expression but did not
affect IFN-c expression. It has been shown that IL27 promotes
Th1 polarization of CD4
+ lymphocytes though activation of
STAT1 and the expression of T-bet [33]. On the other hand it
also induces Tr1 regulatory lymphocytes that can in turn limit
the Th1 response [33]. Previous studies have shown that IL-27
not only induces Th1 lymphocyte differentiation, but can at the
same time suppress them, preventing excessive inflammation [8–
10]. These findings may explain why we were not able to detect
a change in the Th1 response in our model. Furthermore,
subretinal IL-27p28 gene transfer caused a twofold increase in
the ocular IL-10 expression during the clinical EAU episode as
compared to controls receiving the GFP vector. Although the
subretinal IL-27p28 gene transfer had a marked effect on the
intraocular inflammation, we were not able to detect an effect
on systemic immune response parameters including DTH,
lymphocyte proliferation or production of relevant cytokines.
This indicates that subretinal rAAV2-CMV-mIL-27p28 does not
affect the afferent phase of EAU induction but exerts its
inhibitory effect during the effector phase by local modulation
of IL-17 and IL-10 production. Further confirmation is needed
to show that IL27p28 transfection of retinal cells really blocks
TH17 cell function. Experiments using IL27p28 transfected
retinal explants co-cultured with T cells would be necessary to
prove this.
As the EAU model used in this study is self-healing and has a
short duration, it is difficult to study the effect of rAAV2-CMV-
mIL-27p28 on an established intraocular inflammation. This issue
could be addressed by studying the effect of IL-27p28 gene
transfer on a chronic relapsing model of uveitis [34].
IL-27 is a heterodimer normally composed of two subunits
namely Ebi3 and IL-27p28, whereby the Ebi3 subunit has been
shown to be involved in the proper signaling and secretion of IL-
27p28 [6,35]. We only transfected the latter subunit and it would
be interesting to investigate whether the use of the heterodimer
would have a more pronounced effect on the EAU disease course
and its associated intraocular cytokine response. In conclusion, we
showed that subretinal injection of a rAAV2-CMV-mIL-27p28
construct achieved detectable and prolonged expression of mIL-
27p28 protein within the eye and was able to control the severity
of EAU. The inhibitory effect was attributed not only to the
abundant mIL-27p28 secretion but also to the down-regulated of
IL-17 expression and up-regulated IL-10 expression.
Materials and Methods
Ethics Statement
All experimental protocols were developed according to the
Ethics Committee of the First Affiliated Hospital of Chongqing
Medical University, Chongqing, China (Permit Number: 2009-
201009) and in accordance with the Association for Research in
Vision and Ophthalmology (ARVO) statement for the use of
animals in Ophthalmic and Vision Research.
Animals and Reagents
B10RIII mice were purchased from Jackson Laboratory (Bar
Harbor, ME). All animals were housed under specific pathogen
free conditions. Human interphotoreceptor retinoid binding
protein peptide spanning amino acid residues 161–180
(IRBP161–180, SGIPYIISYLHPGNTILHVD) was synthesized by
Shanghai Sangon Biological Engineering Technology & Services
Ltd. Co. Complete Freund’s Adjuvant (CFA) containing 1.0 mg/
ml mycobacterium tuberculosis (H37RA, ATCC 25177) was
purchased from Sigma-Aldrich (St. Louis, MO).
Figure 4. Intraocular cytokines immunoassay on day 12 and day 21. Normal mice and mice receiving a subretinal injection and a subsequent
IRBP immunization were sacrificed on day 12 and day 21 post-immunization. The ocular cytokine levels were assayed by ELISA. IFN-c (A), IL-17 (B) and
IL-10 (C) levels in rAAV2-CMV-mIL-27p28 treated eyes compared with rAAV2-CMV-GFP treated eyes (p values 0.009 and 0.772 were obtained by a
paired T test. The p value 0.024 was calculated using the Mann-Whitney U test). Results are presented as mean 6 standard deviation. ND=not
detected. (n=5).
doi:10.1371/journal.pone.0037773.g004
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The recombinant adeno-associated virus vector,rAAV2-CMV-
mIL-27p28 (mouse IL-27p28, GenBank no. BC119402.1) was
prepared as follows. Total mRNA was extracted from mouse
splenocytes using RNeasy Plus Mini Kit (QIAGEN, Valencia, CA)
and first-strand cDNA was synthesized with the Superscript III
Reverse Transcriptase system (Invitrogen, Carlsbad, CA, USA).
The coding sequence of mIL-27p28 was amplified using the
following primers: forward, 59 GGGGGTACCATGGGC-
CAGGTGACAGGA 39 and reverse, 59 TCTGTCGACTTAG-
GAATCCCAGGCTGAG 39. The PCR product was inserted into
T vector and T-mIL-27p28 was verified by DNA sequencing on
the Applied Biosystems Model 3730 DNA Sequencing System
(Invitrogen Biotechnology Co., Shanghai, China). The mIL-27p28
coding sequence was cut from T- mIL-27p28 with KpnI and SalI,
and then subcloned into an AAV2-CMV backbone between the
sites of KpnI and SalI. After sequence verification, large-scale
production and purification of the vector was performed by Vector
Gene Technology Company Ltd. Vector rAAV2-CMV-GFP
was used as a control. The titers of vector batches were
8.7610
11 v.g./ml for rAAV2-CMV-mIL-27p28 and 1610
12
v.g./ml for rAAV2-CMV-GFP, respectively.
Subretinal Injection
The pupil of mice was dilated with 1% atropine eyedrops
following general anesthesia with an intraperitoneal injection of
pentobarbital (0.1 g/kg). Subretinal injection was performed
under sterile conditions according to the method reported
previously [36]. A 30-gauge needle was use to make an aperture
within the pupil area through the cornea. A blunt 33-gauge needle
was carefully inserted through the corneal aperture avoiding
damage to the lens and penetrating the neuroretina. With the aid
Figure 5. Systemic immune responses following subretinal IL-27p28 gene transfer. In vivo DTH (A), in vitro IRBP-specific lymphocyte
proliferation (B) and IFN-c and IL-17 (C, D) production showed no significant difference among PBS treated mice, rAAV2-CMV-mIL-27p28 and rAAV2-
CMV-GFP treated mice (p.0.05). Results are presented as mean 6 standard deviation. (n=5).
doi:10.1371/journal.pone.0037773.g005
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subretinal space in 30 seconds. The sign of retinal blebs indicated a
successful delivery. Antibiotic ointment was used daily for three
days following subretinal injection. Successfully injected mice
without surgical complications including temporal corneal edema,
anterior or posterior synechiae, cataract and vitreous or retinal
hemorrhage were used for further study as described below.
Intraocular Cytokine Immunoassay
Mice only receiving a subretinal injection of rAAV2-CMV-
mIL-27p28 or rAAV2-CMV-GFP were sacrificed at various time
points. Serum were collected for assay of IL-27p28. Normal mice
and another group of mice receiving a subretinal injection and a
subsequent immunization with IRBP161–180 peptide and CFA
were sacrificed on day 12 and day 21 post-immunization. For
ocular fluid sample preparation, the injected eye and contralateral
eye were enucleated. The conjunctival and optic tissues were
carefully removed and the globes were briefly sonicated with
homogenizing solution(20% glycerol, 10 mM KCl, 2 mM MgCl2,
0.1% Triton, 300 mM NaCl, 0.5 mM dithiothreitol, 20 mM
HEPES and Anti-protease Complete TM cocktail in H2O, 10 ml/
mg). After centrifugation at 110006g for 5 min, supernatants from
homogenized eyes were collected. Concentrations of IL-27p28, IL-
17, IL-10 and IFN-c were determined using commercially
available ELISA kits according to the manufacturer’s directions
(R&D System, Minneapolis, MN) with a detection limit of
15.6 pg/ml, 15.6 pg/ml, 31.3 pg/ml and 31.3 pg/ml respectively.
Induction and Clinical Assessment of EAU
Human IRBP161–180 peptide was solubilized in PBS and
emulsified 1:1 v/v in complete Freund’s adjuvant (CFA) supple-
mented with 1.0 mg/ml mycobacterium tuberculosis strain (MTB). A
total of 200 ml emulsion containing 50 mg human IRBP161–180
peptide was given subcutaneously at the base of the tail and both
thighs for each mouse. Clinically visible EAU was evidenced by
conjunctival hyperemia, ciliary injection, corneal edema, aqueous
flare and cells, and posterior synechiae. Clinical scores of EAU
were recorded by slit lamp microscopy on day 12 after
immunization. The clinical severity of ocular inflammation was
scored on a scale of 0–5 in half-point increments in a masked
manner, based on five separate criteria described previously [29].
Histopathology
Eyes were enucleated on day 14 after immunization and fixed in
4% buffered formaldehyde for 1 hour at room temperature.
Tissues were embedded in paraffin. A 4–6 mm vertical serial
section was cut through the papillary-optic nerve axis and stained
by haematoxylin and eosin. The intensity of EAU was graded by
light microscopy in a masked fashion on a scale of 0 to 4, as
described earlier [37].
Assay for Delayed Type Hypersensitivity
Nineteen days after immunization the mice were anesthetized
by intraperitoneal injection of pentobarbital (0.1 g/kg) and ear
thickness of both ears measured with a micrometer. Human
IRBP161–180 peptide (10 mg) in 10 ml PBS was injected into the
right pinna of each mouse, whereas 10 ml PBS was injected into
the left pinna as a control. Forty-eight hours later, the mice were
anesthetized with pentobarbital and ear thickness was measured
again. Specific ear swelling was calculated as the difference in
thickness (in mm) of the right ear minus the difference in thickness
(in mm) of the left ear.
IRBP-specific Lymphocyte Responses
The spleen and draining lymph nodes were collected from
immunized mice on day 21. A single cell suspension was prepared.
Cells (2610
6 cells/ml) were cultured in a 96-well plate in triplicate
with RPMI 1640 medium (Gibco, Grand Island, NY, USA)
containing 2 mM L-glutamine, 5610-5 M2-ME, 1 mM sodium
pyruvate, 0.1 Mm nonessential amino acids and 10% FBS and
challenged with 10 mg/ml IRBP161–180, 1 mg/ml Concanavalin
A (Sigma) or medium alone for 72 hours. The lymphoproliferative
response was detected by a modified MTT assay using a cell
counting kit (Cell Counting Kit-8; Sigma) as described previously
[38]. IL-17 and IFN-c concentrations in the supernatants were
measured using commercially available ELISA kits according to
the manufacturer’s directions (R&D System, Minneapolis, MN)
with a detection limit of 15.6 pg/ml and 31.3 pg/ml respectively.
Statistical Analysis
Data are expressed as mean 6 standard deviation (SD). Severity
of EAU was analyzed using the Kruskal-Wallis test followed by the
Mann-Whitney U test. Expression of cytokines within the eyes was
analyzed using the Paired T test and Mann-Whitney U test. DTH,
lymphocyte proliferation and cytokine production were analyzed
using ANOVA. A p value below 0.05 was considered to be
significantly different. All experiments were repeated at least twice.
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